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Introduction {#sec1}
============

Professional phagocytes cells represent the first line of host defense against bacterial pathogens. To eradicate pathogenic bacteria, professional phagocytes employ myriad host cell-surface receptors that bind the target bacterium directly (e.g., bacterial surface sugars) or indirectly through host-derived opsonins (e.g., antibodies, complement) ([@bib5], [@bib41]). Receptor binding triggers polymerization of actin filaments that guide the plasma membrane around the pathogen to facilitate bacterial uptake and destruction within an intracellular microbicidal phagolysosome compartment. The actin polymerization requires Rho GTPases Rac1 and Cdc42 that anchor by lipid prenylation to the membrane where they recruit and activate myriad cellular effectors responsible for directing cytoskeleton remodeling via the Arp2/3 complex ([@bib4], [@bib31]).

Counteracting phagocytosis is a central paradigm in bacterial pathogenicity. For example, to inhibit opsonin-dependent *trans-*phagocytosis *Staphylococcus aureus* secretes protein A, which sequesters antibodies, while several pathogens use cell-surface capsule polysaccharides to inhibit deposition of complement ([@bib5], [@bib41]). However, phagocytes offset this strategy through myriad non-opsononic phagocyte receptors that directly bind bacteria and mediate *cis*-phagocytosis independent of opsonins. Nevertheless, uniting the diverse uptake mechanisms is the role of the actin cytoskeleton whose remodeling is required for phagocytosis ([@bib31]). Consequently, pathogens have evolved sophisticated measures to interfere with the actin cytoskeleton and antagonize a spectrum of phagocytic mechanisms at the molecular level.

Enteropathogenic and enterohaemorrhagic *Escherichia coli* (EPEC and EHEC) are major global human health threats causing gastroenteritis and bloody diarrhea, respectively ([@bib18]). To cause disease, they inject a cocktail of virulence effectors into host cells via a type 3 secretion system (T3SS) to enable cell-surface colonization on intestinal epithelia where the pathogen forms lesions characterized by the destruction of brush border microvillii. Here, the bacteria encounter macrophages that infiltrate sites of infection yet EPEC and EHEC are able to block their own phagocytosis through the injected virulence effectors ([@bib40]). Indeed, mutants of type 3 secretion are phagocytosed by macrophages ([@bib17], [@bib30]). Four virulence effectors are known to contribute to anti-phagocytosis ([@bib40]); EspB interacts with the actin binding motor protein myosin-1c ([@bib23]), EspF inhibits PI3 kinase signaling ([@bib6]), EspH inhibits the Dbl subfamily of Rho guanine nucleotide exchange factors (GEFs) ([@bib11]) and EspJ impedes phagocytosis through inhibition of Src kinase activity ([@bib50]).

EPEC and EHEC employ multiple mechanisms to disable phagocytosis. While it is clear that the pathogens target the actin cytoskeleton, we do not yet understand the identity of the cellular actin nucleation machinery governing pathogen phagocytosis and therefore the mechanisms of bacterial interference. Consequently, we first sought to identify the players underlying the actin filament polymerization that are targeted by virulence effectors.

Results {#sec2}
=======

EPEC Opposes Phagocytosis Directed by the WAVE Regulatory Complex {#sec2.1}
-----------------------------------------------------------------

To address how pathogenic *Escherichia coli* resist engulfment by macrophages, we infected differentiated human THP1 macrophage cells with wild-type EPEC (EPEC^WT^) or T3SS-deficient mutant EPEC (EPECΔ^T3SS^) labeled with pHrodo, a pH-sensitive dye that fluoresces red in the low pH of phagosomes and signified pathogen uptake ([Figure 1](#fig1){ref-type="fig"}A). Intracellular bacteria were inaccessible to antibodies against EPEC that marked extracellular bacteria. Only ∼27% of EPEC^WT^ were found intracellular within phagosomes of host cells (actin) and labeling of extracellular bacteria with antibodies demonstrated that the majority of bacteria had counteracted phagocytosis ([Figures 1](#fig1){ref-type="fig"}A and 1B). In contrast, very few extracellular EPECΔ^T3SS^ were observed as ∼92% of bacteria had been phagocytosed. Equivalent results were observed in RAW267.4 mouse macrophage cells ([Figure S1](#mmc1){ref-type="supplementary-material"}A), confirming that EPEC fights phagocytosis using T3SS effectors.

Given the central role of Arp2/3-dependent actin polymerization in phagocytosis ([@bib31]), it seemed likely that EPEC targeted activators of Arp2/3. The WAVE regulatory complex (WRC) is one such activator that is known to drive pathogen macropinocytosis in epithelial cells ([@bib22], [@bib20]) and has been implicated in phagocytosis by *Dictyostelium* ([@bib44]), mammalian granulocytes ([@bib37]), and neutrophils and macrophages ([@bib36]). The WRC is a heteropentameric complex comprising Cyfip, Nap/Hem, Abi, and HSPC300 or their homologs ([@bib14]), which must be activated directly by Rac1 ([@bib32]) in combination with additional potentiating signals including that mediated directly by Arf1 GTPase ([@bib25], [@bib26]). Though whether Rac1 and Arf1 co-operate in WRC-mediated phagocytosis is not known.

To address whether EPEC effectors resist WRC-dependent phagocytosis, THP1 macrophages were depleted of the WRC component Hem by siRNA knockdown before infection with EPECΔ^T3SS^ ([Figures 1](#fig1){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}B, and S1C). In contrast to mock knockdown cells where ∼84% of EPECΔ^T3SS^ were phagocytosed ([Figures 1](#fig1){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}B, and S1C), pathogen uptake was significantly impaired in Hem knockdown cells where it was reduced to ∼33% with the majority of bacteria observed extracellularly ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C). Little is known about WRC regulation in macrophages, and we sought to address the significance of co-operating small GTPases Arf1 and Rac1. Here, knockdown of WRC activators Arf1 and Rac1 also reduced EPECΔ^T3SS^ uptake to ∼38% and ∼35%, respectively ([Figure 1](#fig1){ref-type="fig"}C), which enabled bacteria to remain on the cell surface ([Figure S1](#mmc1){ref-type="supplementary-material"}C) and established that EPEC effectors oppose WRC-dependent phagocytosis regulated by cooperating small GTPases Arf1 and Rac1.

EPEC Effector EspG Disables WAVE Regulatory Complex Activation {#sec2.2}
--------------------------------------------------------------

Given the prominent role of small GTPases in EPECΔ^T3SS^ phagocytosis, we reasoned that EPEC effectors might directly target these players to resist uptake. This strategy is a central virulence strategy employed by many pathogens that deactivate small GTPases through effectors possessing GTPase-activating activity that promote GTP hydrolysis ([@bib10]). Even so, EPEC encodes no known GTPase-activating protein (GAP) of Rac1 or Arf1 and therefore likely uses an alternative mechanism. One possibility included the EPEC effector EspG that was previously shown to act as a molecular scaffold by simultaneously binding the Rac1 effector p21 activated kinase (PAK) and GTP-bound Arf GTPases (e.g., Arf1, Arf6) ([@bib45]). EspG directly activates PAK, while EspG interaction with Arf sterically hinders Arf GAPs, thereby maintaining the GTP-bound form of Arf, which still has portions of its switch 1 and 2 domains exposed to permit interactions with some, but not all, of its cellular effectors ([@bib45], [@bib46]).

First, we examined whether EspG antagonizes WRC-dependent cytoskeleton remodeling by infecting THP1 macrophages with pHrodo-labeled EPEC^WT^ or an isogenic strain with null mutations in espG and its close homolog espG2, henceforth EPECΔ^espG^ ([Figure 1](#fig1){ref-type="fig"}D). In contrast to wild-type bacteria, EPECΔ^espG^ bacteria were incapable of resisting phagocytosis, and ∼85% were observed intracellularly mirroring the phagocytosis of EPECΔ^T3SS^ ([Figures 1](#fig1){ref-type="fig"}B and 1D). Furthermore, this EspG role appears conserved as ΔespG strain of the related pathogen EHEC was also susceptible to phagocytic uptake while wild-type EHEC were resistant ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

We next investigated the mechanism of WRC interference by EspG. The phosphoinositide PIP3 is known to activate the WRC through Rac1 and Arf GTPases ([@bib28], [@bib25]), and PIP3 is a major regulator of pathogen phagocytosis ([@bib9], [@bib6], [@bib38]), but how EPEC counteracts PIP3-driven pathways is unclear. We first reconstituted WRC-dependent actin polymerization driven by PIP3 using a motility assay in cell-free extracts as previously described ([@bib19]). Silica microspheres coated with a phospholipid bilayer containing equal amounts of phosphatidylcholine (PC) and phosphatidylinositol (PI) plus 2% PIP3 (PIP3) were added to cell-free extract containing fluorescent rhodamine-labeled actin and non-hydrolysable GTPγS to activate GTPases. In the control, PIP3 microspheres triggered actin polymerization and generated actin-comet tails (of ∼14 μm) on the membrane surface that propelled the beads through the extract ([Figure 1](#fig1){ref-type="fig"}E). When PIP3-driven motility was examined in extract containing purified recombinant EspG, actin comet tail formation was abrogated and there was no actin assembly on the membrane surface (+EspG). This mirrored the phenotype observed with a Rac1 inhibitor (EHT1864) ([Figure 1](#fig1){ref-type="fig"}E) indicating EspG inhibition of the WRC.

To demonstrate that EspG was blocking WRC activation by Arf1 and Rac1, PC:PI microspheres (i.e., without PIP3) were anchored with purified constitutively active GTP-bound myristoylated Arf1-Q71L (Arf1^QL^) and prenylated Rac1-Q61L (Rac1^QL^) and then added to cell-free extract in the presence or absence of EspG ([Figure 1](#fig1){ref-type="fig"}F). WRC-dependent actin comet tail formation (∼15 μm) was observed in extracts containing PC:PI microspheres co-anchored with Arf1^QL^ and Rac1^QL^, but actin polymerization was abolished in extract containing EspG.

To further examine how EspG disables WRC-dependent actin polymerization, we scaled up the motility assays to isolate the components recruited to the membrane co-anchored with Arf1^QL^ and Rac1^QL^ in the presence or absence of EspG ([Figures 1](#fig1){ref-type="fig"}G and 1H). PC:PI microspheres alone (control) or co-anchored with Arf1^QL^ and Rac1^QL^ were each incubated in cell-free extract with or without recombinant EspG before being isolated and extensively washed then recruited proteins analyzed by SDS-PAGE and immunoblotting ([Figures 1](#fig1){ref-type="fig"}G and 1H). Control microspheres (--) only recruited non-specific proteins, which was also the case when EspG was present ([Figures 1](#fig1){ref-type="fig"}G and 1H). In contrast, microspheres co-anchored with Arf1^QL^ and Rac1^QL^ recruited the WRC components cyfip and Hem ([Figure 1](#fig1){ref-type="fig"}G, green arrows). Their recruitment was confirmed by immunoblotting ([Figure 1](#fig1){ref-type="fig"}H), which also verified the presence of WRC components WAVE and abi1, small GTPases Arf1 and Rac1, and actin derived from comet tails. In contrast, WRC recruitment was impeded (orange arrows) by EspG that was found localized at the membrane, which was dependent upon Arf1^QL^ and Rac1^QL^ ([Figures 1](#fig1){ref-type="fig"}G and 1H). Thus, EspG impedes WRC recruitment and activation, PIP3-mediated actin filament polymerization, and WRC-dependent phagocytosis of EPEC and EHEC.

EspG Targeting of Arf1 Antagonizes WRC-Mediated Phagocytosis {#sec2.3}
------------------------------------------------------------

EspG is a multifunctional virulence effector and may interfere with WRC-mediated cytoskeleton remodeling in several ways: EspG binds active Arf GTPases and deactivates Rab GTPases ([@bib45], [@bib12]), and both Arf and Rab GTPases are known to promote Rac1-dependent actin filament polymerization ([@bib35], [@bib25]). EspG also activates PAK ([@bib45]) that modulates actin filament dynamics, e.g., by deactivating cofilin ([@bib13]). Consistent with a possible role for PAK1, the presence of EspG at membranes co-anchored with Arf1^QL^ and Rac1^QL^ was co-incident with enhanced PAK1 recruitment ([Figure 1](#fig1){ref-type="fig"}H).

To resolve how EspG disables WAVE complex activation, we first purified recombinant EspG mutants ([Figure 2](#fig2){ref-type="fig"}A) incapable of deactivating Rabs (EspGΔ^R^; mutation Q293A) ([@bib12]), binding PAK (EspGΔ^P^; D205A, R208A) ([@bib15]), or binding Arf and PAK (EspGΔ^A^Δ^P^; I152S, P351A, P355A) ([@bib45]) before assessing interference with WRC-dependent actin-based motility directed by Arf1^QL^ and Rac1^QL^ ([Figure 2](#fig2){ref-type="fig"}B). Like EspG^WT^, mutant derivatives EspGΔ^R^ and EspGΔ^P^ both abrogated actin-comet tail formation showing that EspG interaction with PAK and its Rab GAP activity were dispensable for WRC inhibition. This was not the case for EspGΔ^A^Δ^P^, which had no effect on WRC activity as actin comet tails (of ∼14 μm as control) were formed and the microspheres moved through the extract. Thus, EspG targeting of Arf1 and not PAK or Rabs blocked WRC activation.

Consistent with this view, only EspGΔ^A^Δ^P^ was deficient in binding Arf1^QL^-anchored membranes in buffer ([Figure 2](#fig2){ref-type="fig"}C). Moreover, when EspG^WT^ was pre-incubated with membranes co-anchored with Arf1^QL^ and Rac1^QL^ to form an Arf1-EspG complex before incubation in extract, WRC-dependent actin comet tail formation was not observed (data not shown). Furthermore, chemical inhibitors of PAK (i.e., IPA3) have been shown to inhibit activation by EspG ([@bib45]), yet WRC-dependent actin-based motility was observed in PAK-inhibited extract ([Figure S2](#mmc1){ref-type="supplementary-material"}B), reaffirming that EspG inhibits the WRC independently of PAK.

To further examine EspG inhibition of the WRC, we assessed WRC recruitment by Arf1^QL^ and Rac1^QL^ from cell extract in the presence of the EspG derivatives ([Figures 2](#fig2){ref-type="fig"}D and 2E). WRC recruitment to the membrane was obstructed by EspG^WT^, EspGΔ^R^, and EspGΔ^P^ but not EspGΔ^A^Δ^P^ as exemplified by the SDS-PAGE ([Figure 2](#fig2){ref-type="fig"}D, green arrows) and immunoblotting of Hem ([Figure 2](#fig2){ref-type="fig"}E). All EspG variants except EspGΔ^A^Δ^P^ were recruited to Arf1^QL^ and Rac1^QL^ co-anchored membranes. Interestingly, EspGΔ^P^ but not EspGΔ^A^Δ^P^ recruited PAK1 indicating that PAK recruitment was dependent upon the Arf1-EspG interaction and localization of the virulence effector at the membrane.

In parallel, we assessed phagocytic uptake of EPECΔ^espG^ expressing either EspG^WT^, EspGΔ^R^, EspGΔ^P^, EspGΔ^A^Δ^P^, or the empty vector as a control ([Figures 2](#fig2){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}A). THP1 macrophages phagocytosed ∼82% of EPECΔ^espG^ encoding the vector alone, while bacteria expressing EspG^WT^ resisted WRC-dependent uptake that was reduced to ∼35% ([Figures 2](#fig2){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}A), mirroring the resistance imposed by wild-type EPEC ([Figure 1](#fig1){ref-type="fig"}). Similarly, EPECΔ^espG^ expressing EspGΔ^R^ or EspGΔ^P^ also antagonized phagocytosis. In contrast, ∼79% of bacteria expressing EspGΔ^A^Δ^P^ were incapable of resisting the WRC and were phagocytosed to the same extent as the EPECΔ^espG^ vector control strain. Thus, EspG-mediated interaction with Arf GTPases, and not PAK or Rabs, combats WRC-directed pathogen phagocytosis.

Next, we examined whether EspG could counteract the activities of other pathogens dependent upon the WRC. In contrast to extracellular pathogens EPEC and EHEC, *Salmonella* Typhimurium is an intracellular pathogen that invades host epithelial cells by activating the WRC-Rac1-Arf1 axis ([@bib22], [@bib20]). When we examined *Salmonella* invasion in HeLa cells expressing HA-tagged EspG, pathogen uptake was reduced by ∼64% relative to control, which was not observed in cells expressing EspGΔ^A^Δ^P^ ([Figure 3](#fig3){ref-type="fig"}A), thus providing further evidence of EspG interference of WRC-dependent cytoskeleton remodeling.

EspG Incapacitates Arf6 and ARNO Upstream of WRC Activation {#sec2.4}
-----------------------------------------------------------

EspG is known to bind Arf6 in an analogous fashion to Arf1 ([@bib45]), though no function has been ascribed for this host-pathogen interaction. To trigger WRC-dependent invasion, *Salmonella* Typhimurium hijacks Arf6 to recruit and activate the Arf1 GEF ARNO of the cytohesisn family ([@bib20], [@bib49]). We therefore speculated that EspG might also incapacitate WRC activation by inhibiting Arf6 upstream of ARNO-mediated activation of Arf1.

First, we examined whether the cytohesin family (i.e., ARNO) facilitated phagocytosis. THP1 cells treated with the cytohesin inhibitor secinh3 impeded the relative uptake of EPECΔ^espG^ from ∼82% to ∼30% ([Figures 3](#fig3){ref-type="fig"}B and 3C). ARNO is known to facilitate macropinocytosis ([@bib22], [@bib20]), but the uptake of EPECΔ^espG^ was not affected by the macropinocytosis inhibitor eipa ([Figure 3](#fig3){ref-type="fig"}B). Secinh3 but not eipa also inhibited the phagocytosis of EPECΔ^espG^ opsonized with human serum ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Thus, ARNO directs phagocytosis of EPEC, which was counteracted by EspG.

We next examined the mechanism by which EspG antagonized ARNO by reconstituting Arf6-driven activation of WRC as previously reported ([@bib20]). PC:PI microspheres anchored with recombinant myristoylated Arf6 activated with GTPγS were incubated in extract with or without (--) recombinant ARNO ([Figure 3](#fig3){ref-type="fig"}D). Arf6 only triggered actin assembly in the presence of ARNO, but this was abrogated in extract containing EspG^WT^ but not EspGΔ^A^Δ^P^. To determine how EspG impeded Arf6-dependent actin polymerization, PC:PI microspheres were isolated from extract then analyzed by immunoblotting ([Figure 3](#fig3){ref-type="fig"}E). To trigger WRC activation, Arf6 must recruit ARNO ([@bib20]). Indeed, Arf6 alone (-- ARNO) recruited very little Arf1 and Hem, which was enhanced upon addition of recombinant ARNO (+ ARNO). However, in the presence of EspG, Arf6 was incapacitated as the recruitment of ARNO as well as downstream players Arf1 and Hem were impeded. This was not the case with the Arf binding mutant EspGΔ^A^Δ^P^ that had no effect on the Arf6 cascade.

Finally, to investigate whether EspG directly inhibits ARNO via binding to Arf6, we examined interactions in buffer with purified components and PC-coated microspheres ([Figures 3](#fig3){ref-type="fig"}F and 3G) that minimize known ionic interactions between the ARNO plekstrin-homology domain and acidic phospholipids such as PI ([@bib29]). ARNO weakly bound PC microspheres alone, but its recruitment was potentiated by Arf6 ([Figures 3](#fig3){ref-type="fig"}F and 3G). In the presence of EspG^WT^, the virulence effector was recruited through Arf6 that blocked interaction with ARNO ([Figures 3](#fig3){ref-type="fig"}F and 3G). In contrast, the Arf binding mutant EspGΔ^A^Δ^P^ was not recruited by Arf6 and was incapable of impeding ARNO ([Figures 3](#fig3){ref-type="fig"}F and 3G). Thus, EspG directly disables Arf6-dependent actin polymerization by blocking signaling to its cellular effector ARNO.

The Molecular Basis of WRC Interference by EspG {#sec2.5}
-----------------------------------------------

Activated Arf1 mediates interaction with cellular effectors via its switch 1 (residues 40--51) and 2 (68--81) domains ([@bib33]). EspG exhibits an unusual Arf binding interface that is rotated away from the switch 2 site ([Figure 4](#fig4){ref-type="fig"}A) where it interacts with the switch 1 and the alpha-1 helix (29-37) positioned outside of the canonical switch regions ([@bib45]). Consequently, Arf1 bound to EspG can still bind cellular effectors that interact with its switch 2 domain such as the Arf binding GAT domain of GGA vesicle adaptors ([@bib46], [@bib27]) as depicted in [Figure 4](#fig4){ref-type="fig"}A and confirmed experimentally in [Figure S3](#mmc1){ref-type="supplementary-material"}A.

We took advantage of the distinct binding modes of EspG and GAT3 to investigate the mechanism of Arf1-mediated WRC activation and EspG interference. First, we examined actin-based motility in extracts containing equivalent concentrations of either EspG or GAT3 ([Figure 4](#fig4){ref-type="fig"}B). EspG was more potent at inhibiting WRC than GAT3, which impeded robust comet tail formation but still permitted initiation of actin assembly and small comet tails (magnified inset) of ∼8 μm relative to ∼14 μm observed with the control. Indeed, while Arf1^QL^ and Rac1^QL^ recruited both EspG and GAT3 to the membrane ([Figure 4](#fig4){ref-type="fig"}C, GST), EspG but not GAT3 impeded WRC recruitment ([Figure 4](#fig4){ref-type="fig"}C; Hem, [Figure S3](#mmc1){ref-type="supplementary-material"}B, green arrows). It is not known how Arf1 activates the WRC but the results suggested that EspG inhibits recruitment of Arf1 effectors that bind switch 1. This hypothesis was further substantiated by immunoblotting of the switch 1-binding protein AP-1 ([@bib1], [@bib39]) that was recruited in the presence of GAT3 but not EspG ([Figure 4](#fig4){ref-type="fig"}C, AP-1).

EspG interaction with Arf1 is key to inhibiting WRC activation ([Figure 2](#fig2){ref-type="fig"}). Thus, we set out to resolve the molecular basis of EspG interference further by purifying an array of Arf1^QL^ derivatives incorporating mutations within the alpha-1 helix (Y35Q), switch 1 (T45I, I49T), or switch 2 (I74T, Y81H) domain ([Figure 4](#fig4){ref-type="fig"}A), which have been implicated in interactions with EspG or its cellular effectors ([@bib45], [@bib27]). We examined EspG and GAT3 interactions with PC:PI microspheres anchored with each Arf1^QL^ mutant derivative in buffer ([Figures 3](#fig3){ref-type="fig"}D and 3E, and comprehensively shown in [Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). EspG bound control Arf1^QL^ but interaction with anchored Arf1^QL^-Y35Q was completely abolished and though the effector was still recruited by Arf1^QL^-I49T, the interaction was evidently weaker ([Figure 3](#fig3){ref-type="fig"}D). The remaining Arf1 mutations had no effect. In contrast, GAT3 bound each Arf1^QL^ variant equivalently except the switch 2 mutant Arf1^QL^-I74T ([Figure 3](#fig3){ref-type="fig"}E).

EspG Targets Arf1 Residues Essential to Cooperation with Rac1 and WRC Activation {#sec2.6}
--------------------------------------------------------------------------------

As the Arf1 residue Y35, and to a lesser extent I49, likely underlie EspG inhibition of the Arf1-Rac1-WRC axis, we next examined whether these sites in Arf1 were key for collaboration with Rac1 in WRC recruitment and activation at the membrane. In contrast to Arf1^QL^ or Rac1^QL^ alone, only membranes co-anchored with both GTPases (ctrl) triggered recruitment of the WRC ([Figures 5](#fig5){ref-type="fig"}A and 5B) and robust actin comet tail formation ([Figures 5](#fig5){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}A) demonstrating that small GTPase cooperation was required for WRC activation. Interestingly, Arf1^QL^ alone recruited AP-1 ([Figure 5](#fig5){ref-type="fig"}B), a marker for classical Arf1 effectors that binds the alpha-1 helix and switch 1 domain of Arf1 ([@bib1], [@bib39]). However, when Arf1^QL^ combined with Rac1^QL^ (ctrl) the presence of AP-1 was diminished relative to Arf1^QL^ alone, while WRC recruitment was enhanced uncovering a remarkable switch in effector interplay by Arf1 when collaborating with Rac1 ([Figure 5](#fig5){ref-type="fig"}B). Thus, when working in synergy with Rac1 the results indicate that Arf1 recruits and activates the WRC via its alpha-1 helix and switch 1 domain in place of classical effectors such as AP-1.

When we examined the Arf1^QL^ derivatives mutated in the alpha-1 helix, switch-1 or switch-2 domain, they all collaborated with Rac1 by recruiting the WRC ([Figures 5](#fig5){ref-type="fig"}A and 5B and comprehensively shown in [Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). Given this observation, we were surprised to find that certain Arf1 mutations had a substantial impairment in WRC activation ([Figures 5](#fig5){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B). Like Arf1^QL^, mutants Arf1^QL^-T45I, -I74T, and -Y81H formed robust actin comet tails (exemplified by I74Tin [Figure 5](#fig5){ref-type="fig"}C). In contrast, the motility of membranes anchored with Arf1^QL^-Y35Q or -I49T was markedly impaired ([Figure 5](#fig5){ref-type="fig"}C). We noticed that a small proportion of actin shells (∼10%) surrounding the Arf1^QL^-Y35Q and Arf1^QL^-I49T membranes broke symmetry to form stumpy comet tails of ∼2 μm (exemplified by green arrows in [Figure 5](#fig5){ref-type="fig"}C), indicating weak activation of the WRC. We speculated that the weak activation of the WRC by Arf1^QL^-Y35Q would be resistant to interference by EspG, which binds Y35 ([Figure 4](#fig4){ref-type="fig"}D). Sure enough, while EspG blocked the formation of comet tails generated by the switch 2 mutant Arf1^QL^-I74T, stumpy comets were still formed by Arf1^QL^-Y35Q even in the presence of EspG ([Figure 5](#fig5){ref-type="fig"}C).

Finally, as both Arf1 residues Y35 and I49 mediated interaction with EspG ([Figure 4](#fig4){ref-type="fig"}D), we examined WRC recruitment and actin-based motility at membranes anchored with a double mutant ([Figures 5](#fig5){ref-type="fig"}A--5C). Arf1^QL^-Y35Q/I49T was incapable of collaborating with Rac1^QL^ as the WRC was neither recruited ([Figures 5](#fig5){ref-type="fig"}A and 5B) nor activated ([Figure 5](#fig5){ref-type="fig"}C). Thus, EspG targets specific residues in the alpha-1 helix and switch 1 domain of Arf1 that facilitate small GTPase co-operation and actin filament polymerization by the WRC.

Discussion {#sec3}
==========

To avoid phagocytosis bacterial pathogens employ a wide range of strategies. For example, many pathogens secrete immunoglobulin proteases to cleave antibodies and impede FcR-mediated uptake ([@bib41]). However, not all phagocytic mechanisms are driven by opsonization emphasizing the need for other inventive virulence strategies. We show that EPEC and EHEC circumnavigate this problem by inhibiting WRC signaling to the actin cytoskeleton whose remodeling is at the very center of phagocytosis. The role of Rac1 and Arf6 in phagocytosis is well established ([@bib34], [@bib51], [@bib4]), yet the contribution of the WRC ([@bib36]) and Arf1 is less clear ([@bib2], [@bib47]). WRC activation by Arf1 and Rac1 is known to mediate lamellipodia formation and *Salmonella* macropinocytosis into host cells ([@bib21], [@bib20]). Here, we show a crucial role for the WRC in pathogen phagocytosis and establish that collaborating WRC activators Arf1 and Rac1 are required. Structural homologs cyfip and Hem of WRC are thought to oppose the plasma membrane where small GTPases are anchored ([@bib7]). As Rac1 is known to bind cyfip ([@bib24]), it is possible that Arf1 collaborates with Rac1 by binding Hem (depicted in [Figure 6](#fig6){ref-type="fig"}) or through an unidentified Arf1 effector acting as an intermediate. By using EspG to probe the relationship between Arf1 and Rac1, we identify key residues in the Arf1 alpha-1 helix (Y31) and switch-1 domain (I49) that underpin its collaboration with Rac1 in WRC recruitment and activation at the membrane. Interestingly, we found that the equivalent residues in Arf6 (Y31 and V45) were dispensable for Arf6 activation of ARNO ([Figure S5](#mmc1){ref-type="supplementary-material"}), and, although the EspG interactions with Arf6-Y31Q were attenuated as previously reported ([@bib45]), the interactions at the membrane were sufficient to block ARNO-dependent signaling to the WRC mediated by either Arf6-Y31Q or Arf6-V45A ([Figure S5](#mmc1){ref-type="supplementary-material"}). Thus, the sites on Arf6 that permit signaling to ARNO and interference by EspG are distinct from those in Arf1 that cooperate with Rac1 in WRC signaling at the membrane, and perhaps reflect differences in the primary sequence of Arf1 and Arf6 (70% identity).

Given the central role of Rho GTPases in phagocytosis, it is not surprising that many pathogens employ GAPs to deactivate GTPases (e.g., *Yersinia* YopE, *Pseudomonas* ExoS) ([@bib3], [@bib16]). Yet, EPEC and EHEC encode no known GAPs. Instead, the pathogens interfere with Rho GTPase activation through EspH that binds Rho Dbl-family GEFs to disrupt interaction with Rho GTPases ([@bib11]). Here, we show that EPEC and EHEC disarm professional phagocytes through EspG that targets active Arf GTPases to block activation of ARNO and the WRC. EspG is known to sterically hinder Arf interactions with Arf GAPs and certain cellular effectors ([@bib45], [@bib46]). Consistent with this view, we propose that EspG utilizes steric hindrance to prevent Arf GTPase cooperation with Rac1 in driving cytoskeleton remodeling. Thus, EPEC and EHEC likely inhibit WRC-dependent phagocytosis by nullifying both Rho activation via EspH and Arf signaling via EspG.

The study also shows that ARNO, a plasma membrane GEF of Arf1, operates in this phagocytic pathway, which is consistent with a previously reported role for Arf1 and the ARNO homolog cytohesin-1 in opsonin-dependent phagocytosis ([@bib2], [@bib47]). ARNO is activated at the plasma membrane by Arf6 ([@bib49], [@bib8]), a long established regulator of phagocytosis ([@bib34], [@bib51]). EspG directly abrogated Arf6 recruitment and activation of ARNO thereby impeding Arf1 activation and describing a role for the Arf6-EspG interaction.

In summary, by targeting both Arf6 and Arf1 our work establishes a dual mechanism by which a single virulence effector uncouples two arms of the WRC regulatory pathway and ultimately inhibits phagocytic uptake to evade innate host defenses (depicted in our model in [Figure 6](#fig6){ref-type="fig"}).

Experimental Procedures {#sec4}
=======================

Bacterial Strains {#sec4.1}
-----------------

EPEC E2348/69 and EHEC EDL933 (TUV93-0 Shiga toxin deficient derivative) strains were used. Isogenic mutant EPEC ΔespG1/ ΔespG2 (Prof. Feng Shao) and EHEC ΔespG (Dr. Ken Campellone) were kind gifts. For infections, bacteria were cultured as previously described ([@bib48]).

Plasmids {#sec4.2}
--------

The following plasmids were generated by Invitrogen Gateway methodology: pET15b-espG, pGEX2T-espG, pcDNA-HA-espG (encoding effector domain residues 48--398) and pTrc99FA-espG (full length). Plasmids pET20b-Arf1, pET20b-Arf6, pET15b-Rac1, pGEX2T-ARNO-2G, and pGEX2T-GGA3-GAT^1--313^ were described previously ([@bib20]). Point mutations were introduced by site-directed mutagenesis into pET15b-espG, pGEX2T-espG (EspGΔ^P^ residues D205A, R208A; EspGΔ^R^ Q293A; EspGΔ^A^Δ^P^ I152S, P351A, P355A), pET20b-Arf1 or pET20b-Arf6 (mutations indicated in the text). GST- and His-tagged proteins were expressed in *E. coli* Rosetta (Novagen) at 16°C before affinity purification ([@bib22]).

Antibodies {#sec4.3}
----------

Antibodies were purchased from Abcam (Rac1, ab33186; Arf1, ab58578; Arf6, ab81650; ARNO, ab56510; PAK1, ab154284), Sigma (Abi1, A5106; Actin, A2066; Cyfip, P0092; Nap1, N3788; AP1, A4200), GE Healthcare Life Sciences (GST, 27457701), QIAGEN (His, 34660) or were raised against recombinant peptides in rabbits by Diagnostics Scotland (WAVE2, amino acids 180--241). Antibodies against GST or His were used to detect EspG.

Mammalian Cell Culture and Transfection {#sec4.4}
---------------------------------------

The human monocyte-like cell line THP1s (kind gift from Prof. Gordon Dougan) and mouse macrophage-like RAW264.7 (ATCC-TIB71) cells were cultured (37°C, 5% CO~2~) in RPMI-1640 or DMEM in the case of HeLa cells (ATCC-CCL-2) supplemented with 2 mM L-glutamine, 10% heat-inactivated fetal calf serum (FCS), 200 μg/mL^--1^ streptomycin, and 100 U mL^--1^ penicillin ([@bib43]). THP1s were differentiated into mature macrophage-like cells by stimulation with 100 ng/mL Phorbol 12-myristate 13-acaetate (PMA) for 3 days and then cultured for an additional day without PMA before phagocytosis assays.

Transient transfection of HeLa cells by microporation was performed using the Neon Transfection System according to the manufacturer's instructions (Invitrogen). For RNA interference, small interfering RNA (siRNA) smart pools against Arf1, Rac1, and Hem-1 or non-targeting control siRNA from Dharmacon (GE Healthcare Life Sciences) were transfected into THP1 cells with Oligofectamine transfection reagent (Invitrogen) according to manufacturer's instructions. Transfection mixture was replaced after 24 hr with complete growth medium and cells cultured 72 hr in total.

Phagocytosis Assays {#sec4.5}
-------------------

Prior to infection EPEC and EHEC strains were harvested by centrifugation, washed in phosphate-buffered saline (PBS) then incubated with pH-Rodo (Thermo Fisher Scientific) before washing with Tris (pH 7.4)-buffered saline. Approximately 2 × 10^5^ mammalian cells seeded onto glass coverslips were infected with pH-Rodo-labeled bacteria (1 hr, 37°C, 5% CO~2~) before washing with PBS and fixation using 4% paraformaldehyde. Fixed cells were incubated with rabbit anti-intimin (EPEC/EHEC outer membrane protein) antibodies, washed with PBS, and then incubated with anti-rabbit Alexa Flour 350 antibodies and cells visualized phalloidin-FITC-488 (Thermo Fisher Scientific) in PBS supplemented with Tx100. Phagocytosis was quantified by counting the number of extracellular bacteria labeled with intimin antibodies relative to intracellular bacteria showing pH-Rodo fluorescence using automated Volocity software (Improvision). When appropriate, cells were incubated with 25 μM Secinh3 (Merck). Immunofluorescence microscopy and images assembled as described ([@bib22]). All experiments were performed at least three times.

*Salmonella* Invasion of Non-phagocytic Host Cells {#sec4.6}
--------------------------------------------------

Wild-type *Salmonella enterica* serovar Typhimurium SL1344 were used to assay invasion into non-phagocytic cells as previously described ([@bib20]). *Salmonella* encoding pM975 that expresses GFP via the SPI2 promoter when bacteria are within *Salmonella* containing vacuoles (SCVs) ([@bib42]) were used to infect HeLa cells (10 min), and the number of fluorescent bacteria was counted per cell microscopically.

In Vitro WRC-Dependent Actin-Based Motility {#sec4.7}
-------------------------------------------

Preparation of porcine brain extract, actin-based motility by phospholipid-coated beads, and isolation of bead membrane-associated proteins have been described in detail ([@bib19]). When indicated, extract or buffer containing recombinant EspG derivatives, GAT3, or ARNO was used. Quantification of comet tail length was performed on 50 comet tails per experiment using Volocity measurement software (Improvision). All experiments were performed at least three times.

Statistics {#sec4.8}
----------

All experiments were performed at least three times. Geometric means were calculated, and significance was determined by Student's t test or one-way ANOVA followed by a post hoc Dunnett's comparison. ^∗^p \< 0.05 was considered significant.
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![EspG Interference of the WAVE Regulatory Complex\
(A) Phagocytosis of pH-Rodo-labeled wild-type and ΔT3SS EPEC. Merged images show intracellular bacteria (red), extracellular bacteria (blue), and host cells (actin). Grayscale shown for clarity. Scale bars, 6 μm.\
(B) Bar chart quantifying phagocytosis from experiment in (A).\
(C) Phagocytosis of EPECΔ^T3SS^ (ΔT3SS) in THP1s transfected with Hem, Rac1, or Arf1 siRNA.\
(D) Phagocytosis of EPECΔ^espG^ (ΔespG). Asterisks indicate a significant difference from control (black bars).\
(E) Actin-based motility of PIP3-containing microspheres (depicted in cartoon) in cell-free extract containing a Rac1 inhibitor (+EHT1864) or EspG. Insets magnify actin-comet tails. Scale bars, 5 μm.\
(F) WRC-dependent actin-based motility of PC:PI phospholipid bilayers microspheres co-anchored with Arf1^QL^ and Rac1^QL^ in cell-free extract containing fluorescent rhodamine-actin in the presence (+EspG) or absence (control) of recombinant EspG.\
(G) Proteins recruited by PC:PI-coated microspheres alone (control) or co-anchored with Arf1^QL^ and Rac1^QL^ (colored circles) from extract (--/+ EspG) were analyzed by SDS-PAGE and Coomassie blue staining. Green arrows indicate cyfip, Hem, or actin. Orange arrows indicate absence of cyfip and Hem. Molecular weight markers in kilodaltons (left).\
(H) Immunoblotting of samples from (G) with indicated antibodies (right).\
In bar charts (B)--(D), error bars represent ± SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![EspG Interaction with Arf GTPase Blocks the WRC\
(A) Cartoon depicting key residues (white) in EspG (black) responsible for interaction with Rabs (green), PAK (blue), or Arf (purple).\
(B) WRC-dependent actin-based motility via membrane-anchored Arf1^QL^ and Rac1^QL^ (depicted in cartoon) alone (control) or in the presence of EspG, namely, wild-type (WT) or mutants in binding Rab (EspGΔ^R^), PAK (EspGΔ^P^) or both Arf and PAK (EspGΔ^A^Δ^P^).\
(C) Interaction of EspG derivatives with membrane-anchored Arf1^QL^ in buffer.\
(D) Proteins recruited by membrane-anchored Arf1^QL^ and Rac1^QL^ (colored circles) in the presence or absence of EspG derivatives as (B) analyzed by SDS-PAGE. Molecular weight markers in kilodaltons (left).\
(E) Immunoblotting of samples from (D) with indicated antibodies (right).\
(F) Phagocytosis of EPECΔ^espG^ (ΔespG) expressing a control vector or the vector encoding espG variants described in (B).\
Error bars represent ± SEM. Asterisks indicate a significant difference from control (black bars). ns, not significant. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![EspG Incapacitation of Arf6 Signaling to ARNO and the WRC\
(A) *Salmonella* invasion by macropinocytosis into non-phagocytic HeLa cells expressing a control vector or the vector encoding wild-type EspG (espG^WT^) or a mutant in binding both Arf and PAK (espGΔ^A^Δ^P^). Values for invasion were normalized to the control\
(B) THP1 phagocytosis of EPECΔ^espG^ (ΔespG) in the presence of inhibitors of ARNO (secinh3) or macropinocytosis (eipa). Asterisks indicate a significant difference from control (black bars). Not significant (ns). See also [Figure S3](#mmc1){ref-type="supplementary-material"}C.\
(C) Imaging of phagocytosed EPECΔ^espG^ (ΔespG) bacteria (red) and THP1 actin cytoskeleton (green) from experiment in (B). Scale bars, 4 μm.\
(D) WRC-dependent actin assembly via membrane-anchored Arf6^GTPγS^ (depicted in cartoon) in cell-free extract alone or in extract containing recombinant ARNO in the presence or absence of recombinant EspG derivatives described in (A).\
(E) Immunoblotting of proteins recruited from cell extract by phosphatidylcholine:phosphatidylinositol (PCPI) membranes anchored with Arf6^GTPγS^ in the presence of ARNO and EspG derivatives described in (A).\
(F) The interaction of PC membranes alone (left) or membranes anchored with GTPγS-loaded Arf6 with His-ARNO (red arrow) or GST-EspG (green arrow) alone, or both in combination, in buffer. Asterisks indicate Arf6 dimers.\
(G) Immunoblotting of samples from (A) with indicated antibodies against GST (EspG), ARNO, and Arf6 (right).\
In bar charts (A) and (B), error bars represent ± SEM.](gr3){#fig3}

![Molecular Basis of WRC Interference by EspG\
(A) Cartoon depicting Arf1 interaction with EspG or GAT3 of GGA3 with key residues and domains in Arf1 shown.\
(B) WRC-dependent actin-based motility directed by Arf1^QL^ and Rac1^QL^ in extract alone (control), or with GAT3 or EspG. Insets magnify actin-comet tails. Scale bars 5 μm.\
(C) Immunoblotting of proteins recruited by membrane-anchored Arf1^QL^ and Rac1^QL^ from extract alone (ctrl), or from extract containing EspG or GAT3, or both in combination. Anti-GST antibodies detected GAT3 and EspG.\
(D) Interaction of EspG with PCPI membranes alone (--) or with membranes anchored with Arf1^QL^ (ctrl) or Arf1^QL^ derivatives containing indicated mutations.\
(E) Experiment performed as (B) with GAT3.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![EspG Targets Arf1 Residues Essential to Synergy with Rac1 and WRC Activation\
(A) WRC-dependent actin-based motility directed by Rac1^QL^ alone (--) or in combination with Arf1^QL^ (ctrl) or in combination with Arf1^QL^ containing indicated mutations. Insets magnify actin-comet tails. Scale bars, 5 μm.\
(B) Proteins recruited by membrane-anchored Arf1^QL^ or Rac1^QL^ alone or Rac1^QL^ in combination with Arf1^QL^ containing indicated mutations as (A). Green arrows indicate cyfip and Hem.\
(C) Immunoblotting of samples from (B) with indicated antibodies (right).\
(D) WRC-dependent actin-based motility directed by Rac1^QL^ in combination with indicated Arf1^QL^ mutants in extract containing EspG. Insets magnify actin-comet tails. Scale bars, 5 μm.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Model for EspG Incapacitation of the WRC\
(A) Arf6 recruits and activates ARNO that activates Arf1 which consequently anchors via its exposed myristoylation moiety to the plasma membrane (brown lines). While the Arf1 binding partner remains speculative (e.g., Hem), nevertheless, membrane anchored active Arf1 and Rac1 work in synergy to recruit and activate the WRC (i.e., release of the WAVE veroprolin homology cofilin hemology acidic region \[VCA\] domain) that induces Arp2/3-dependent polymerization of actin filaments (red) and pathogen phagocytosis. Empty (GDP) and filled blue (GTP) circles.\
(B) EspG interaction with Arf GTPases blocks actin polymerization via a dual mechanism: EspG impedes Arf6-activation of ARNO and Arf1-activation of the WRC (highlighted by the red cross).](gr6){#fig6}
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